Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid-Reference-Cited by-同舟云学术

Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid

Published:2021-02-18 Issue:3 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

de Vos Margaretha¹^ORCID,Scott Lesley²,David Anura²^ORCID,Trollip Andre¹,Hoffmann Harald³⁴,Georghiou Sophia¹,Carmona Sergio¹,Ruhwald Morten¹,Stevens Wendy²⁵,Denkinger Claudia M.¹⁶^ORCID,Schumacher Samuel G.¹^ORCID

Affiliation:

1. Foundation for Innovative New Diagnostics, Geneva, Switzerland

2. Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

3. Institute of Microbiology and Laboratory Medicine, Department IML Red GmbH, WHO-Supranational Reference Laboratory of Tuberculosis, Munich-Gauting, Germany

4. SYNLAB Gauting, SYNLAB Human Genetics Munich, Munich-Gauting, Germany

5. National Health Laboratory Services, Johannesburg, South Africa

6. Division of Tropical Medicine, Center of Infectious Diseases, University Hospital of Heidelberg, Heidelberg, Germany

Abstract

Failure to rapidly identify drug-resistant tuberculosis (TB) increases the risk of patient mismanagement, the amplification of drug resistance, and ongoing transmission. We generated comparative analytical data for four automated assays for the detection of TB and multidrug-resistant TB (MDR-TB): Abbott RealTi m e MTB and MTB RIF/INH (Abbott), Hain Lifescience FluoroType MTBDR (Hain), BD Max MDR-TB (BD), and Roche cobas MTB and MTB-RIF/INH (Roche).

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.02168-20

Reference25 articles.

1. World Health Organization. 2018. Global tuberculosis report 2018. World Health Organization, Geneva, Switzerland.

2. World Health Organization. 2008. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). World Health Organization, Geneva, Switzerland.

3. World Health Organization. 2016. The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin. World Health Organization, Geneva, Switzerland.

4. World Health Organization. 2011. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational “how-to”; practical considerations. World Health Organization, Geneva, Switzerland.

5. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy;Microbiology Spectrum;2024-01-11

2. Two-stage tuberculosis diagnostics: combining centrifugal microfluidics to detect TB infection and Inh and Rif resistance at the point of care with subsequent antibiotic resistance profiling by targeted NGS;Lab on a Chip;2024

3. Microbiological tests and laboratory tests: the value of point-of-care testing;The Challenge of Tuberculosis in the 21st Century;2023-09-01

4. Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing;PLOS ONE;2023-08-24

5. Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization–Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis and Resistance to Rifampicin and Isoniazid;The Journal of Molecular Diagnostics;2023-01